Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The pathogenesis of metastasis is a complex biological process with many interacting factors. The role of immune response in the control of metastasis, though recognized as one of the important factors, is still poorly understood. Concomitant tumor immunity (CTI) to both autochthonous and syngenic tumors is strikingly potent in terms of the size of tumor cell challenge it is capable of rejecting [51,71]. The observation that tumors that are highly metastatic have poor CTI [23,46] indicates that immune response to a progressive tumor has a potent role in controlling the metastatic spread.Increased metastasis observed following generalized immunosuppression [7, 20,41,60] or specific suppression of T cells [11, 15] and macrophages [8,34] and in deficiency of natural killer cell activity such as is normal in beige mice [68] indicates the role of different components of the immune system in the control of metastasis.However, studies on the cells infiltrating the tumor, which would reflect the immune control at the site of the tumor, have given varied results. The nature of infiltrating cells within the tumor mass varies from tumor to tumor, and the nature of effector cells found within the tumor may or may not correlate with what is found in the spleen or peripheral lymph nodes or in the blood of the same tumor-bearing animals [28]. Husby et al. [33] have shown that T cells predominante in the infiltrates of primary tumors and the pattern remains the same regardless of anatomic site or of the presence or absence of metastasis. In contrast, B cells predominate at the margin of a metastasis. Mononuclear cells bearing Fc receptors were not a prominent component of the infiltrate associated with either primary tumor or metastasis. Currie [10] and Alexander and Eccles [2] have shown that metastatic tumors contain Reprint request should be addressed to: M. Seshadri few macrophages and the localized tumors contain a wide range, but tending toward a higher number of macrophages. Nonmetastasizing and metastasizing lymphomas produce similar responses in the lymph node weight gain assay, but host cell infiltration in the tumor growing subcutaneously was much greater in nonmetastasizing than in metastasizing tumors. The infiltrating cells were found to be Fc receptor-positive, and matured into macrophages after 2 days in culture [11]. In experimental systems, macrophage infiltration has been found to be directly proportional to immunogenicity and inversely proportional to metastatic capacity [13]. Dependence of macrophage infiltration on the thymic function has been shown in studies where heterozygous nude mice show higher infiltration into tumors than do homozygous nude mice [64], and animals subjected to thymectomy and irradiation show less infiltration into tumors than normal mice [13]. Thus macrophage infiltration might reflect host immune reaction to the tumor. In keeping with a contribution of the infiltrating cells to the control of metastasis, when tumor cells were depleted of macrophages before implantation an increas...
The pathogenesis of metastasis is a complex biological process with many interacting factors. The role of immune response in the control of metastasis, though recognized as one of the important factors, is still poorly understood. Concomitant tumor immunity (CTI) to both autochthonous and syngenic tumors is strikingly potent in terms of the size of tumor cell challenge it is capable of rejecting [51,71]. The observation that tumors that are highly metastatic have poor CTI [23,46] indicates that immune response to a progressive tumor has a potent role in controlling the metastatic spread.Increased metastasis observed following generalized immunosuppression [7, 20,41,60] or specific suppression of T cells [11, 15] and macrophages [8,34] and in deficiency of natural killer cell activity such as is normal in beige mice [68] indicates the role of different components of the immune system in the control of metastasis.However, studies on the cells infiltrating the tumor, which would reflect the immune control at the site of the tumor, have given varied results. The nature of infiltrating cells within the tumor mass varies from tumor to tumor, and the nature of effector cells found within the tumor may or may not correlate with what is found in the spleen or peripheral lymph nodes or in the blood of the same tumor-bearing animals [28]. Husby et al. [33] have shown that T cells predominante in the infiltrates of primary tumors and the pattern remains the same regardless of anatomic site or of the presence or absence of metastasis. In contrast, B cells predominate at the margin of a metastasis. Mononuclear cells bearing Fc receptors were not a prominent component of the infiltrate associated with either primary tumor or metastasis. Currie [10] and Alexander and Eccles [2] have shown that metastatic tumors contain Reprint request should be addressed to: M. Seshadri few macrophages and the localized tumors contain a wide range, but tending toward a higher number of macrophages. Nonmetastasizing and metastasizing lymphomas produce similar responses in the lymph node weight gain assay, but host cell infiltration in the tumor growing subcutaneously was much greater in nonmetastasizing than in metastasizing tumors. The infiltrating cells were found to be Fc receptor-positive, and matured into macrophages after 2 days in culture [11]. In experimental systems, macrophage infiltration has been found to be directly proportional to immunogenicity and inversely proportional to metastatic capacity [13]. Dependence of macrophage infiltration on the thymic function has been shown in studies where heterozygous nude mice show higher infiltration into tumors than do homozygous nude mice [64], and animals subjected to thymectomy and irradiation show less infiltration into tumors than normal mice [13]. Thus macrophage infiltration might reflect host immune reaction to the tumor. In keeping with a contribution of the infiltrating cells to the control of metastasis, when tumor cells were depleted of macrophages before implantation an increas...
The responsiveness of spleen cells from C57BL/6J mice to various immunogenic stimuli was examined during the progressive growth of a poorly immunogenic fibrosarcoma T241. A strong correlation was observed between the progressive tumor growth and the depression of response to Concanavalin A, lipopolysaccharide, sheep red blood cells, and alloantigens in mixed lymphocyte reaction and cell-mediated lympholysis (CML). The maximum depression of these immune responses occurred when the animals had grown tumors for 3-4 weeks. Furthermore, serum from these animals collected 20 days after tumor transplantation was highly immunosuppressive. The possible mechanisms of tumor-induced immunosuppression have been discussed.
A synthetic peptide (RS-83277) derived from the structure of human C-reactive protein (CRP) was previously shown to have antitumor activity in three different murine tumor models when administered in multilamellar vesicles (MLV). The therapeutic effects were comparable to those seen with MLV-encapsulated native CRP. The present study evaluated the therapeutic and immunomodulatory effects of administering CRP peptide RS-83277 MLV simultaneously with low-dose recombinant interleukin-2 (IL-2) to C57Bl/6 mice bearing established pulmonary metastases of fibrosarcoma T241. Results demonstrated that the capacity of RS-83277 MLV to inhibit tumor metastases and prolong survival was significantly augmented by combination with 10,000 U/day IL-2 i.p. Treated animals showed no evidence of toxicity. By immunohistochemistry, increased Thy 1.2+ cells were detectable in lungs of RS-83277 MLV/IL-2-treated animals compared to those receiving RS-83277 MLV alone. Circulating tumor necrosis factor alpha (TNF) and interferon (IFN) were not detectable in animals receiving RS-83277 MLV alone, but TNF was significantly elevated in animals receiving IL-2. In the presence of combination therapy, however, circulating TNF was not detectable. Results suggest that the combination of synthetic CRP peptide RS-83277 MLV and low-dose IL-2 offers a therapeutic advantage over either agent alone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.